source
- FDA staff flag no major concerns for Grail's multi-cancer test ahead of advisory committeeFDA staff have completed a review of Grail's multi-cancer early detection test and reported no major concerns. The assessment comes as the test approaches a scheduled advisory committee meeting, w…
- Compass eyes J&J’s Spravato playbook for upcoming psychedelic drug COMP360 launchCompass executives told BioPharma Dive that, if the FDA approves their treatment, they plan to follow the commercial strategy Johnson & Johnson used for its ketamine spray Spravato. When Spravato…